The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medibank (MPL) CEO Craig Drummond is stepping down from his role on June 30, marking the end of five years with the company
  • Before he departs, Drummond says the company will continue its focus on preventative healthcare, short stay programs, clinical homecare and access to virtual care
  • Medibank Chairman Mike Wilkins has praised Drummond for his tenure saying he’s leaving the company in a stronger position
  • Medibank Private shares are trading 3.36 per cent lower at $2.79

Medibank (MPL) CEO Craig Drummond is stepping down from his role on June 30, marking the end of five years with the company.

Before his departure, Drummond says the company will continue to focus on working to deliver more preventative healthcare, short stay programs, clinical homecare and access to virtual care, such as telehealth.

”Pleasingly, Medibank is on a clear strategic path to grow the private health insurance business at a faster rate and continue the transformation into a broader healthcare company,” Drummond said.

“’I could not have been blessed with a more competent executive leadership team or supportive board,” he continued.

Medibank Chairman Mike Wilkins praised Drummond for his contribution.

“Craig has done a wonderful job in leading and transforming Medibank. He will leave the company in a much stronger position, on a clear strategic path, with a great team. This is the mark of outstanding leadership,” Mike said.

Investors appear to be wary about the management shake-up, with Medibank shares closing  3.36 per cent lower at $2.79.

MPL by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…